DarioHealth Corp. announced on June 24, 2025, groundbreaking research findings presented at the 85th Annual American Diabetes Association Scientific Sessions. The studies, marking Dario's 25th published research at the ADA, highlight the platform's critical contributions to digital health. Key findings include sustained outcomes for GLP-1 users and advanced AI-powered personalization.
One landmark study revealed that GLP-1 users engaging with Dario's platform achieved a dramatic eA1c reduction from 9.0% to 6.7%. Crucially, these users maintained stable outcomes, with no significant weight or glucose rebound, for at least six months after discontinuing GLP-1 medication. This addresses a significant industry challenge of rebound effects post-treatment.
Additionally, AI research demonstrated an 89% predictive accuracy for future blood glucose levels, showcasing Dario's ability to deliver value in chronic condition management. The company is actively leveraging these findings in commercial discussions with payers and self-insured employers, particularly for GLP-1 optimization programs, to maximize investment in costly medications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.